NCT06863766

Brief Summary

This study aims to conduct a 8-week intervention involving one formula milk powder for middle-aged and elderly individuals with pre-diabetes, assessing its impact on blood glucose control and fluctuations in comparison to interventions using regular milk powder.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 7, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

April 10, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2026

Completed
Last Updated

April 3, 2025

Status Verified

March 1, 2025

Enrollment Period

8 months

First QC Date

March 3, 2025

Last Update Submit

March 31, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • fasting blood glucose

    At baseline, and 8 weeks, investigators will use automatic electrochemiluminescence analyzer to examine fasting blood glucose.

    up to 8 weeks

  • 2h-piAUC after standardized breakfast

    the positive increment of area under curve in 2 hours after standardized breakfast standardized breakfast, measured by continuous glucose monitoring at baseline, and 8 weeks.

    up to 8 weeks

  • TIR (time in range)

    TIR refers to the time when blood glucose is controlled within a reasonable ( target ) range (3.9\~10.0 mmol/L), measured by continuous glucose monitoring at baseline and 8 weeks.

    up to 8 weeks

Secondary Outcomes (7)

  • HbA1c

    up to 8 weeks

  • weight

    up to 8 weeks

  • intestinal bacteria

    up to 8 weeks

  • lipid metabolism

    up to 8 weeks

  • sleep quality

    up to 8 weeks

  • +2 more secondary outcomes

Study Arms (2)

fortified formula milk powder group

EXPERIMENTAL

Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.

Dietary Supplement: fortified formula milk powder group

regular milk powder group

PLACEBO COMPARATOR

Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.

Dietary Supplement: regular milk powder group

Interventions

Fortified formula milk powder is supplemented with fiber, bitter gourd powder,mulberry leaves extract, whitekidney beans extract, and probiotics, and packaged in 25-gram sachets. The milk powder is consumed orally, two sachets per day for a duration of 8 weeks.

fortified formula milk powder group
regular milk powder groupDIETARY_SUPPLEMENT

Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.

regular milk powder group

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 40 and 75 years, regardless of gender.
  • Impaired fasting glucose (5.6 mmol/L ≤ FPG \< 6.9 mmol/L) or glycated hemoglobin (HbA1c) between 5.7-6.4% (39-47 mmol/mol).
  • Resided in Guangzhou for the past six months and no plans to relocate or travel outside the city in the next month.
  • Signed informed consent form and voluntarily agreed to participate in the project.

You may not qualify if:

  • Patients with a confirmed diagnosis of diabetes who are currently taking glucose-lowering medications (e.g., insulin, GLP-1 receptor agonists, or SGLT2 inhibitors).
  • Individuals with lactose intolerance or dairy product intolerance.
  • Pregnant, planning to become pregnant within the next three months, or currently breastfeeding.
  • Weight change \> 5% in the past three months or plans to lose weight or change dietary habits.
  • Alcohol consumption \> 40g/day.
  • Individuals with communication barriers, cognitive impairments, or other conditions that may prevent them from completing the study procedures.
  • Severe diseases that may affect participation in the study, including but not limited to endocrine disorders, severe cardiovascular or cerebrovascular diseases, cancer, metabolic diseases, etc.
  • Participation in or current involvement in other clinical trials within the past three months.
  • No use of antibiotic medications within the past three months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Glucose Intolerance

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 3, 2025

First Posted

March 7, 2025

Study Start

April 10, 2025

Primary Completion

December 20, 2025

Study Completion

March 30, 2026

Last Updated

April 3, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share